CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 8-K — Jun 26, 2026
$CEROForm 8-KItems 1.01, 2.03, 3.02, 9.01Filed Jun 26, 2026, 8:00 AM ET0001213900-26-072602Original filing
CERO Therapeutics Holdings, Inc. entered into an amended and restated convertible promissory note with SRX Health Solutions, Inc., increasing the total available financing to $1,413,600. The agreement amends a previous $750,000 note issued in May 2026 and includes an immediate funding of $663,600 on June 23, 2026. The note matures on May 28, 2027, bears a 10% annual interest rate, and includes a 25% original issue discount that increases the principal obligation.
Key figures
- Debt Amount
- $1,413,600
- Interest Rate
- 10%
- Maturity Date
- May 28, 2027
- Floor Price
- $0.05
- Ownership Cap
- 4.99%
- New Funding Date
- June 23, 2026
- New Funding Amount
- $663,600
- Conversion Discount
- 80% of lowest VWAP
- Prior Funding Amount
- $750,000
- Original Issue Discount
- 25%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.